University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Items where Author is "Tayebi, M"

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 27.

Article

David, MA, Jones, DR and Tayebi, M (2014) Potential candidate camelid antibodies for the treatment of protein-misfolding diseases JOURNAL OF NEUROIMMUNOLOGY, 272 (1-2). pp. 76-85.

Tayebi, M, Jones, DR, Taylor, WA, Stileman, BF, Chapman, C, Zhao, D and David, M (2011) PrP(Sc)-specific antibodies with the ability to immunodetect prion oligomers. PLoS One, 6 (5).

Tayebi, M, David, M, Bate, C, Jones, D, Taylor, W, Morton, R, Pollard, J and Hawke, S (2010) Epitope-specific anti-prion antibodies upregulate apolipoprotein E and disrupt membrane cholesterol homeostasis. J Gen Virol, 91 (Pt 12). pp. 3105-3115.

Bate, C, Tayebi, M and Williams, A (2010) Glycosylphosphatidylinositol anchor analogues sequester cholesterol and reduce prion formation. J Biol Chem, 285 (29). pp. 22017-22026.

Bate, C, Tayebi, M and Williams, A (2010) A glycosylphosphatidylinositol analogue reduced prion-derived peptide mediated activation of cytoplasmic phospholipase A2, synapse degeneration and neuronal death. Neuropharmacology, 59 (1-2). pp. 93-99.

Bate, C, Tayebi, M and Williams, A (2010) The glycosylphosphatidylinositol anchor is a major determinant of prion binding and replication. Biochem J, 428 (1). pp. 95-101.

Bate, C, Tayebi, M, Salmona, M, Diomede, L and Williams, A (2010) Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro. Neurotox Res, 17 (3). pp. 203-214.

Bate, C, Tayebi, M and Williams, A (2010) Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration. Mol Neurodegener, 5.

Jones, DR, Taylor, WA, Bate, C, David, M and Tayebi, M (2010) A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines. PLoS One, 5 (3).

Tayebi, M, Collinge, J and Hawke, S (2009) Unswitched immunoglobulin M response prolongs mouse survival in prion disease. J Gen Virol, 90 (Pt 3). pp. 777-782.

Bate, C, Tayebi, M, Diomede, L, Salmona, M and Williams, A (2009) Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines. PLoS One, 4 (12).

Bate, C, Tayebi, M and Williams, A (2008) Cholesterol esterification reduces the neurotoxicity of prions. Neuropharmacology, 54 (8). pp. 1247-1253.

Bate, C, Tayebi, M, Diomede, L, Salmona, M and Williams, A (2008) Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells. BMC Biol, 6.

Bate, C, Tayebi, M and Williams, A (2008) Ginkgolides protect against amyloid-beta1-42-mediated synapse damage in vitro. Mol Neurodegener, 3.

Bate, C, Tayebi, M and Williams, A (2008) Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation. BMC Biol, 6.

Tayebi, M, Bate, C, Hawke, S and Williams, A (2007) A role for B lymphocytes in anti-infective prion therapies? Expert Rev Anti Infect Ther, 5 (4). pp. 631-638.

Tayebi, M and Hawke, S (2006) Antibody-mediated neuronal apoptosis: therapeutic implications for prion diseases. Immunol Lett, 105 (2). pp. 123-126.

Khalili-Shirazi, A, Quarantino, S, Londei, M, Summers, L, Tayebi, M, Clarke, AR, Hawke, SH, Jackson, GS and Collinge, J (2005) Protein conformation significantly influences immune responses to prion protein. J Immunol, 174 (6), 15749856. pp. 3256-3263.

Beringue, V, Vilette, D, Mallinson, G, Archer, F, Kaisar, M, Tayebi, M, Jackson, GS, Clarke, AR, Laude, H, Collinge, J and Hawke, S (2004) PrPSc binding antibodies are potent inhibitors of prion replication in cell lines. J Biol Chem, 279 (38). pp. 39671-39676.

Tayebi, M, Enever, P, Sattar, Z, Collinge, J and Hawke, S (2004) Disease-associated prion protein elicits immunoglobulin M responses in vivo. Mol Med, 10 (7-12). pp. 104-111.

Beringue, V, Mallinson, G, Kaisar, M, Tayebi, M, Sattar, Z, Jackson, G, Anstee, D, Collinge, J and Hawke, S (2003) Regional heterogeneity of cellular prion protein isoforms in the mouse brain. Brain, 126 (Pt 9). pp. 2065-2073.

White, AR, Enever, P, Tayebi, M, Mushens, R, Linehan, J, Brandner, S, Anstee, D, Collinge, J and Hawke, S (2003) Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature, 422 (6927). pp. 80-83.

Conference or Workshop Item

Tayebi, M, Vendruscolo, M and David, MA (2011) Anti-oligomer monoclonal antibodies reveal that protein aggregation modulates generalized physiological and pathological disturbances In: PrioNet & Neuroprion, 2011-05-16 - 2011-05-19, Monteal Canada.

Tayebi, M and David, MA Canine spongiform encephalopathy-A new form of animal prion disease In: NEUROPRION, 2012-05-09 - 2012-05-12, AMSTERDAM, THE NETHERLANDS.

Tayebi, M, Sattar, Z, Kaisar, M, Khallili-Shirazi, A, Mallinson, G, Jackson, GS, Collinge, J and Hawke, S PrP conformation and genotype profoundly influence anti-PrP antibody specificity In: Immunology, 2011 - ?, UK.

Patent

UNSPECIFIED ANTIBODIES SPECIFIC FOR MISFOLDED PROTEINS AND METHODS FOR THEIR PRODUCTION WO Patent 2,010,015,834.

UNSPECIFIED CARRIER WO Patent 2,010,038,035.

This list was generated on Sat Sep 23 22:05:19 2017 UTC.

Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800